Full-Time

Sr. Scientist

Bioanalytical, PK/Ada

Confirmed live in the last 24 hours

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Compensation Overview

$108.6k - $157.3kAnnually

+ Annual Bonus + Equity Incentive Program

Senior

Company Does Not Provide H1B Sponsorship

San Diego, CA, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • BS/BA degree in Biology or closely related field and 5+ years of industry experience in a biotech, pharma, and/or CRO setting; Experience working in and accomplishing tasks in a timeline-driven setting; Experience in large molecules or biomarkers bioanalysis is preferred OR
  • MS/MA degree in Biology or closely related field and 3+ years of similar experience noted above OR
  • PhD or equivalent and some industry experience; may include postdoc experience
  • Degree in biology, chemistry, or related science, preferably with experience in a bioanalytical laboratory
  • Background in bioanalytical job-relevant core competency (immunoassays such as ELISA, handling of a variety of biological matrices such as serum and plasma, automation, method development/validation GLP studies, biomarker analysis)
  • Hands-on experience with role-appropriate technology and methodology such as: automation, radioisotope use, PK analysis and modeling and simulation software
  • Previous experience in cross-functional teams and in a scientific or clinical setting supporting drug development
  • Developing strong written and verbal communication skills
  • Knowledge of regulatory requirements for bioanalytical assays
  • Experience with the generation of immunoassay critical reagents and reagent life cycle management
  • Developing the ability to recognize anomalous and inconsistent results and interprets experimental outcomes
  • Developing strong knowledge of scientific principles, methods and techniques
  • Ability to work with a variety of laboratory instrumentation and/or PK analysis and or modeling and simulation software
  • Excellent computer skills
  • Developing problem-solving, analytical thinking skills
  • Ability to meet multiple deadlines, with a high degree of accuracy and efficiency
Responsibilities
  • Develop custom reagents and assays on various platforms (e.g., ELISA, electrochemiluminescence, Gyros) for pharmacokinetic and/or immunogenicity assessments
  • Perform sample analysis to support bioanalysis efforts for non-regulated and regulated preclinical studies, including pharmacokinetics, pharmacodynamics, immunogenicity, and biological activity
  • Lead the development and qualification of ADA assays (e.g. bridging electrochemiluminescence) to assess immunogenicity in biologic programs
  • Work collaboratively with internal stakeholders to support CRO selection and oversee the transfer of internal assays to support regulated preclinical studies
  • Lead troubleshooting efforts for both bioanalytical internal methods as well as methods at CROs to ensure data quality
  • Effectively communicate results to internal/external teams in presentations and internally authored reports
  • Prepare documents to support technical transfer of methods to CROs
  • Manage and maintain a safe, organized, and operational laboratory space including maintenance of equipment and procurement of supplies
  • May QC study reports and regulatory submissions
  • Performs other duties as assigned
Desired Qualifications
  • Experience in large molecules or biomarkers bioanalysis is preferred
  • Developing strong written and verbal communication skills
  • Developing problem-solving, analytical thinking skills
Neurocrine Biosciences

Neurocrine Biosciences

View

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • Neurocrine's R&D pipeline benefits from government incentives for rare disease research.
  • The launch of CRENESSITY offers a novel approach to treating congenital adrenal hyperplasia.
  • Neurocrine's collaboration with Takeda accelerates osavampator's development for major depressive disorder.

What critics are saying

  • Increased competition in neuroscience could impact Neurocrine's market share.
  • Financial burden from osavampator development may affect Neurocrine's R&D budget.
  • Reliance on PANTHERx Rare for CRENESSITY distribution poses logistical risks.

What makes Neurocrine Biosciences unique

  • Neurocrine focuses on under-addressed neurological, neuroendocrine, and neuropsychiatric disorders.
  • CRENESSITY is the first non-steroidal treatment for classic congenital adrenal hyperplasia.
  • Neurocrine has exclusive worldwide rights to develop osavampator, except in Japan.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Parental Leave

Health Insurance

Dental Insurance

Vision Insurance

Paid Holidays

Company News

PR Newswire
Mar 11th, 2025
Neurocrine Biosciences To Present At The Stifel 2025 Virtual Cns Forum

SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief Executive Officer Kyle Gano and Chief Medical Officer Eiry Roberts will present at the conference.The live webcast can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.About Neurocrine BiosciencesNeurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders

PR Newswire
Feb 21st, 2025
Neurocrine Biosciences Board Of Directors Authorizes $500 Million Share Repurchase Program

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025.William Rastetter, Chairman of the Board of Directors of Neurocrine Biosciences, said, "This authorization reflects our approach to capital allocation that balances driving sustained revenue growth through investing in our commercial products, INGREZZA and CRENESSITY, advancing our expanding R&D pipeline and returning capital to shareholders."Under the new authorization, repurchases may be made from time to time at management's discretion through a variety of methods, such as open-market transactions including pre-set trading plans, privately negotiated transactions, accelerated share repurchases, and other transactions in accordance with applicable securities laws.About Neurocrine BiosciencesNeurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life- changing treatments for patients with under-addressed neuropsychiatric, neurological, and neuroendocrine disorders. The company's diverse portfolio includes U.S

PR Newswire
Jan 27th, 2025
Neurocrine Biosciences Announces Amendment To Strategic Collaboration With Takeda To Develop And Commercialize Osavampator (Formerly Nbi-1065845/Tak-653)

- Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to Royalty-Bearing License for Osavampator- Takeda Reacquires Rights to Osavampator in JapanSAN DIEGO, Jan. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the amended agreement, Neurocrine will obtain exclusive rights for all indications to develop and commercialize osavampator, a potential first-in-class AMPA positive allosteric modulator in development for patients with inadequate response to treatment of major depressive disorder (MDD) in all territories worldwide except Japan, where Takeda will reacquire exclusive rights. Under the terms of the updated agreement, each company is responsible for development costs in their respective region, and both companies are eligible to receive royalty payments."This streamlined collaboration structure allows Neurocrine to focus on bringing this important medicine to patients as quickly as possible," said Kyle Gano, Ph.D., Chief Executive Officer at Neurocrine Biosciences. "With the recent successful completion of our End-of-Phase 2 meeting with FDA for osavampator, we look forward to beginning the Phase 3 program in the first half of this year.""With its long-standing expertise developing therapies for serious psychiatric disorders, Neurocrine is the ideal partner to develop osavampator," said Sarah Sheikh, M.Sc., B.M., B.Ch, MRCP, Head, Neuroscience Therapeutic Area Unit and Head, Global Development at Takeda

PR Newswire
Jan 21st, 2025
Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today In The Journal Of Clinical Endocrinology Metabolism

SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM), sponsored by the company. The supplement, titled "Challenges and Opportunities in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Throughout the Lifetime," contains eight review articles that provide a comprehensive look at the clinical, psychosocial, treatment-related and day-to-day challenges faced by individuals with classic CAH. JCEM is a leader in disseminating research that supports healthcare providers, patients and caregivers in advancing the understanding and management of various endocrinology conditions, such as CAH."Our understanding of the genetics, pathophysiology, and complications of CAH has exploded over the last 20 years," said Dr. Richard Auchus, M.D., Ph.D., Principal Investigator, Professor of Pharmacology and Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes at the University of Michigan

ForexTV
Jan 14th, 2025
Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio

Nxera and Neurocrine entered a collaboration and licensing agreement in 2021 to develop a portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Nxera for the treatment of schizophrenia, dementia and other neuropsychiatric disorders.